每经AI快讯，中红医疗（SZ 300981，收盘价：14.02元）11月17日晚间发布公告称，公司第四届第十四 次董事会会议于2025年11月17日以通讯方式召开。会议审议了《关于聘任董事会秘书的议案》等文件。 2025年1至6月份，中红医疗的营业收入构成为：医疗器械行业占比100.0%。 截至发稿，中红医疗市值为60亿元。 （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——展望"十五五" | 专访尹艳林：让有钱且愿消费的人顺利消费；个税起征点可 提高，最高边际税率可下调，让有关群体少缴税、多收入 ...

每经头条（nbdtoutiao）——展望"十五五" | 专访尹艳林：让有钱且愿消费的人顺利消费；个税起征点可 提高，最高边际税率可下调，让有关群体少缴税、多收入 每经AI快讯，中红医疗（SZ 300981，收盘价：14.02元）11月17日晚间发布公告称，因个人原因，张琳 波先生申请辞去公司董事会秘书等职务，不再担任公司及下属子公司任何职务。张琳波先生辞去公司董 事会秘书等职务后，不再担任公司及下属子公司任何职务。公司审议通过了《关于聘任董事会秘书的议 案》，同意聘任邓伟先生为公司第四届董事会的董事会秘书。 2025年1至6月份，中红医疗的营业收入构成为：医疗器械行业占比100.0%。 截至发稿，中红医疗市值为60亿元。 （记者 张明双） ...

中红普林医疗用品股份有限公司（以下简称"公司"）于近日收到公司首次 公开发行股票并在创业板上市的保荐机构国泰海通证券股份有限公司（以下简称 "国泰海通证券"）出具的《国泰海通证券股份有限公司关于更换中红普林医疗 用品股份有限公司持续督导保荐代表人的函》，由于原保荐代表人邓伟先生因工 作变动原因，无法继续从事公司的持续督导工作，为保证持续督导工作的有序进 行，国泰海通证券现委派保荐代表人葛龙龙先生接替邓伟先生继续履行持续督导 工作，保荐代表人葛龙龙先生简历详见附件。 证券代码：300981 证券简称：中红医疗 公告编号：2025-102 中红普林医疗用品股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 二〇二五年十一月十七日 附件： 保荐代表人葛龙龙先生简历 葛龙龙先生，男，中国国籍，现任国泰海通证券投资银行部高级副总裁，保 荐代表人。2015 年起从事投资银行业务，曾负责或参与益诺思 IPO、之江生物 IPO、中红医疗 IPO、起帆电缆 IPO、森麒麟轮胎 IPO、东方材料 IPO、界龙实业 增发、世茂股份增发、天 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-101 中红普林医疗用品股份有限公司 关于董事会秘书辞职及聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会秘书辞职情况 上市公司董事会秘书培训证明，在取得上市公司董事会秘书培训证明前，董事会 指定邓伟先生代行董事会秘书职责，待邓伟先生取得董事会秘书资格证书后，正 式履行董事会秘书职责。 邓伟先生联系方式如下： 特此公告 中红普林医疗用品股份有限公司 董事会 二〇二五年十一月十七日 中红普林医疗用品股份有限公司（以下简称"公司"）董事会于近日收到公 司董事会秘书张琳波先生提交的书面辞职报告，因个人原因，张琳波先生申请辞 去公司董事会秘书等职务，根据相关规定，张琳波先生的辞职报告自送达董事会 之日起生效。张琳波先生辞去公司董事会秘书等职务后，不再担任公司及下属子 公司任何职务。 张琳波先生担任董事会秘书的原定任期为 2024 年 7 月 15 日至 2027 年 7 月 15 日。截至本公告日，张琳波先生未直接或间接持有公司股份，不存在应当履 行而未履行的承诺事项。公司 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-100 二、会议审议情况 1. 审议通过《关于聘任董事会秘书的议案》 鉴于张琳波先生申请辞去公司董事会秘书等职务，根据《公司法》《公司章 程》的有关规定，经公司董事会薪酬考核与提名委员会资格审核，董事会同意聘 任邓伟先生为公司第四届董事会的董事会秘书，上述任期自本次董事会审议通过 之日起至第四届董事会任期结束之日止。 该议案已经第四届董事会薪酬考核与提名委员会第六次会议全体成员审议 通过。 表决结果为：同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《关于董事会秘书辞职及聘任董事会秘书的公告》（公告编号：2025-101）。 中红普林医疗用品股份有限公司 第四届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十四 次会议于 2025 年 11 月 17 日以通讯方式召开，2025 年 11 月 12 日公 ...

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, benefiting from the depreciation of the RMB and focusing on innovation in medical products [2][4][3]. Group 1: Company Overview - Zhonghong Medical is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The company was established on December 22, 2010, and went public on April 27, 2021. Its main business includes the research, production, and sales of high-quality nitrile gloves and PVC gloves [9]. - The revenue composition of the company is as follows: health protection products 89.48%, safety infusion products 6.22%, and innovative incubation products 4.30% [9]. Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38%. However, the net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10]. - As of September 30, 2025, the company had a total market capitalization of 5.905 billion yuan, with a trading volume of 61.734 million yuan and a turnover rate of 1.14% [1]. Group 3: Market Position and Trends - The company’s overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. - Zhonghong Medical participated in the 12th Beijing Pet Expo, showcasing its veterinary infusion pumps, which received positive feedback for their safety and multifunctionality [2][3]. - The company aims to integrate digital technology into product development, focusing on high-quality and innovative medical consumables and equipment [3].

Core Insights - Zhonghong Medical's subsidiary, Kelong Medical, has successfully participated in bulk procurement projects across multiple provinces, enhancing its market presence in the medical consumables sector [1][2]. Group 1: Procurement Success - Kelong Medical has won bids for essential medical consumables such as vacuum blood collection tubes, nebulizers, intravenous catheters, and infusion sets in various provinces including Fujian, Beijing, and Yunnan [2]. - The selected products are recognized as clinical necessities, indicating stable market demand and a strong competitive edge [2][3]. Group 2: Product Strength and Market Performance - The products selected for procurement have established a solid reputation and customer base, demonstrating their market competitiveness through consistent performance [3]. - Kelong Medical's core products have maintained robust market performance, supported by precise understanding of clinical needs and ongoing product optimization [3]. Group 3: Market Expansion and Long-term Development - The bulk procurement initiative is a significant opportunity for Kelong Medical, promising stable market orders and expanded market space [4]. - The procurement rules ensure that medical institutions prioritize Kelong Medical's selected products, which will enhance market share and brand influence [4]. - This breakthrough in procurement is a critical advancement for Zhonghong Medical in the medical consumables sector, allowing for better alignment with industry trends and improved supply chain efficiency [4]. Group 4: Future Growth Prospects - The successful procurement is a testament to Kelong Medical's long-term focus on product quality and market strategy [5]. - With the anticipated signing and execution of procurement contracts, Kelong Medical is expected to further increase market coverage and share, driving sustainable growth for Zhonghong Medical [5]. - This achievement opens new development avenues and positions the company to lead in the high-quality development wave of the medical consumables industry [5].

Core Viewpoint - 中红医疗 is experiencing growth in its stock price and market activity, driven by its focus on medical devices, pet economy, and international sales, particularly benefiting from the depreciation of the RMB [1][4]. Group 1: Company Overview - 中红医疗 primarily engages in ODM production for overseas medical device brands, focusing on self-designed and self-manufactured products [2]. - The company was established on December 22, 2010, and went public on April 27, 2021, specializing in high-quality disposable protective gloves and medical supplies [9]. - As of September 30, 2025, 中红医疗 reported a revenue of 1.864 billion yuan, a year-on-year increase of 1.38%, but a net profit loss of 7.21 million yuan, a decrease of 114.13% year-on-year [10]. Group 2: Product and Market Focus - 中红医疗 showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which are designed for safety and multifunctionality [2]. - The company emphasizes innovation and digital technology integration in developing high-performance medical products to meet diverse market needs [3]. - In 2024, overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Financial and Shareholder Information - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan in the last three years [11]. - As of September 30, 2025, the number of shareholders increased to 22,400, with an average of 17,531 shares held per person, a decrease of 10.11% from the previous period [10].

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]

Core Viewpoint - The announcement by Zhonghong Medical on November 4 indicates that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), has participated in bidding for centralized procurement projects in multiple cities and provinces, with potential selection of several products [1] Group 1: Procurement Projects - Kelong Medical is involved in bidding for centralized procurement projects in Putian City, Fuzhou City, Beijing, and Qujing City [1] - The products targeted for selection include disposable vacuum blood collection tubes, disposable nebulizers, and disposable intravenous indwelling needles [1] Group 2: Market Impact - If selected, the medical institutions in the procurement regions will prioritize the use of Kelong Medical's products during the procurement cycle, ensuring the completion of the agreed procurement volume [1] - The subsequent signing of sales contracts and implementation will help expand the market sales of the selected products, increase market share, and enhance brand influence, positively impacting the company's long-term development [1]